## Edgar Filing: Babu Yarlagadda S - Form 4

Babu Yarlagadda Form 4											
January 23, 2018 FORM 4		TATES SEC	TIDITIES A	ND FX(	THAT	NCF	OMMISSION		PPROVAL		
Check this box	Washington, D.C. 20549								3235-0287 January 31,		
if no longer subject to Section 16. Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Estimated a	Expires: 2005 Estimated average burden hours per		
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17(a)	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type Respo	nses)										
Babu Yarlagadda S Symbol BIOCRY			ssuer Name <b>and</b> ool CRYST PHA [BCRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 3. Date of			te of Earliest Tr th/Day/Year)	ansaction			Director 10% Owner Officer (give title Other (specify below) below) Senior VP - Drug Discovery				
(	(Street)	Amendment, Da Month/Day/Year	-			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
DURHAM, NC	27703							Aore than One Re			
(City)	(State) (Z	Zip) ]	fable I - Non-D	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned		
		ction Date 2A. Deemed bay/Year) Execution Date, if any (Month/Day/Year)		3.4. Securities AcquiredTransaction(A) or Disposed ofCode(D)(Instr. 8)(Instr. 3, 4 and 5)			SecuritiesIBeneficially(OwnedI	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Comment			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				
Common 01/ Stock	/20/2018		F	3,872 (1)	D	\$ 5.59	99,996	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Babu Yarlagadda S - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	ress Relationships						
	Director	10% Owner	Officer	Other			
Babu Yarlagadda S 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703			Senior VP - Drug Discovery				
Signatures							
/s/ Alane P. Barnes, by power of attorney	of	01/23/2018					
<u>**</u> Signature of Reporting Person		Da	te				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Accenture plc Class A ordinary shares from Accenture pursuant to the Accenture Senior Executive Voluntary Equity Investment Program.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.